Rebecca Epperly, MD, on Emerging Clinical Research With Cell Therapy in Leukemia, Lymphoma

Video

The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.

“The big areas we see people addressing in the CAR space is how to prevent relapse, or treat patients who relapse after they've gotten the first round of CD19 CAR T cells? And then how do we get to other groups? … Those are really kind of key areas of interests moving forward that we've been seeing a lot in the preclinical space. And this is kind of one of the first rounds of seeing this very early clinical data come out.”

The cellular immunotherapies session at 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana, highlighted early clinical data on emerging therapies including Unicar-T-CD123 for relapsed/refractory (R/R) acute myeloid leukemia (AML), UCART123v1.2 in the same indication, and CD30.CAR-T cells in classical Hodgkin lymphoma (CHL).

CGTLive spoke with the session’s moderator Rebecca Epperly, MD, instructor and clinician scientist, bone marrow transplant and cellular therapy, St. Jude Children’s Research Hospital, about her insights into the presentations and current trends in early clinical research in acute leukemias and HL. She touched on some of these trends, including addressing treatment after relapse with chimeric antigen receptor (CAR) T-cell therapy and underrepresented areas of disease with cell therapy.

Click here to read more coverage of the ASH 2022 meeting.

REFERENCE
Epperly R. Cellular Immunotherapies: Early Phase and Investigational Therapies: Acute Leukemia and Hodgkin Lymphoma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans. Session 704.
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.